Clinical Trial Update: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC [Phase 1]

View source ↗

Summary

A Phase I study to evaluate the safety, tolerability, and pharmacokinetics of HLX3901 in patients with advanced small cell lung cancer or neuroendocrine carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• HLX3901

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: SCLC, NEC | Phase 1 | Status: NOT_YET_RECRUITING